Highlights and Quick Summary
- Total non-current liabilities for the quarter ending June 29, 2021 was $107 Billion (a 1.79% increase compared to previous quarter)
- Year-over-year quarterly Total non-current liabilities decreased by -3.14%
- Annual Total non-current liabilities for 2020 was $109 Billion (a 33.18% increase from previous year)
- Annual Total non-current liabilities for 2019 was $81.7 Billion (a 61.6% increase from previous year)
- Annual Total non-current liabilities for 2018 was $50.6 Billion (a 3.08% increase from previous year)
Visit stockrow.com/ABBV
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Total non-current liabilities of AbbVie Inc.
Most recent Total non-current liabilitiesof ABBV including historical data for past 10 years.Interactive Chart of Total non-current liabilities of AbbVie Inc.
AbbVie Inc. Total non-current liabilities for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2021 | $106,694.0 | $104,817.0 | – | – | – |
| 2020 | $108,807.0 | $110,151.0 | $110,152.0 | $82,143.0 | $108,807.0 |
| 2019 | $81,702.0 | $50,174.0 | $48,767.0 | $50,691.0 | $81,702.0 |
| 2018 | $50,559.0 | $53,698.0 | $47,792.0 | $48,731.0 | $50,559.0 |
| 2017 | $49,048.0 | $49,120.0 | $48,726.0 | $51,822.0 | $49,048.0 |
| 2016 | $51,682.0 | $51,054.0 | $52,299.0 | $38,415.0 | $51,682.0 |
| 2015 | $38,211.0 | $41,156.0 | $37,093.0 | $14,272.0 | $38,211.0 |
| 2014 | $14,378.0 | $17,174.0 | $17,510.0 | $17,744.0 | $14,378.0 |
| 2013 | $17,827.0 | $17,800.0 | $17,547.0 | $17,446.0 | $17,827.0 |
| 2012 | $16,869.0 | $1,693.25 | $1,364.76 | $1,395.84 | $16,869.0 |
| 2011 | – | – | – | $1,692.0 | $1,692.0 |
| 2010 | $1,670.45 | – | – | – | $1,670.46 |
Business Profile of AbbVie Inc.
Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.